Repligen Corporation (NASDAQ:RGEN – Get Free Report) shares shot up 6.6% on Wednesday. The stock traded as high as $171.56 and last traded at $172.8110. 165,943 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 1,060,255 shares. The stock had previously closed at $162.18.
Wall Street Analyst Weigh In
Several research analysts recently commented on the company. UBS Group reiterated a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Royal Bank Of Canada raised their target price on shares of Repligen from $185.00 to $200.00 and gave the stock an “outperform” rating in a report on Wednesday, October 28th. Wells Fargo & Company increased their target price on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Finally, Barclays raised their price objective on Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $178.57.
Read Our Latest Report on RGEN
Repligen Stock Down 1.4%
The company has a market cap of $10.88 billion, a P/E ratio of 84.64, a PEG ratio of 2.96 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.43 and a current ratio of 9.88. The firm’s 50-day simple moving average is $177.19 and its 200 day simple moving average is $145.93.
Repligen (NASDAQ:RGEN – Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.07. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The company had revenue of $209.31 million during the quarter, compared to analysts’ expectations of $206.70 million. During the same period in the prior year, the firm earned $0.46 earnings per share. Repligen’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, research analysts forecast that Repligen Corporation will post 2.07 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. North Dakota State Investment Board increased its position in Repligen by 4.1% in the 3rd quarter. North Dakota State Investment Board now owns 1,630 shares of the biotechnology company’s stock valued at $313,000 after buying an additional 64 shares in the last quarter. Bessemer Group Inc. boosted its position in shares of Repligen by 38.0% in the 3rd quarter. Bessemer Group Inc. now owns 334 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 92 shares in the last quarter. Wealth Alliance LLC boosted its position in shares of Repligen by 3.7% during the third quarter. Wealth Alliance LLC now owns 2,636 shares of the biotechnology company’s stock valued at $507,000 after buying an additional 93 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in Repligen by 35.5% in the third quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 98 shares during the period. Finally, Eurizon Capital SGR S.p.A. lifted its holdings in Repligen by 21.2% during the third quarter. Eurizon Capital SGR S.p.A. now owns 583 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 102 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.
About Repligen
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
Further Reading
- Five stocks we like better than Repligen
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
